Testing the Use of Fulvestrant and Binimetinib Targeted Treatment for NF1 Mutation in Hormone Receptor-Positive Metastatic Breast Cancer (A ComboMATCH Treatment Trial)
National Cancer Institute (NCI)
National Cancer Institute (NCI)
Sanofi
Dana-Farber Cancer Institute
M.D. Anderson Cancer Center
Taiho Oncology, Inc.
M.D. Anderson Cancer Center
Hoffmann-La Roche
Novartis
GlaxoSmithKline
Genentech, Inc.
Novartis
University of Wisconsin, Madison
Puma Biotechnology, Inc.
University of California, Irvine
ArQule, Inc., a subsidiary of Merck Sharp & Dohme LLC, a subsidiary of Merck & Co., Inc. (Rahway, NJ USA)
Hoffmann-La Roche
Hoffmann-La Roche
University of Maryland, Baltimore
Emory University
Eli Lilly and Company
Icahn School of Medicine at Mount Sinai
Translational Oncology Research International
Elevation Oncology
Novartis
Celgene
OHSU Knight Cancer Institute
Western Regional Medical Center
Sanofi
Novartis
M.D. Anderson Cancer Center
University of Southern California